Loading...
•
Mar 31, 2021
Edgewise Therapeutics Q1 2021 Earnings Report
Edgewise Therapeutics' financial position was strengthened by the successful IPO, and clinical development of EDG-5506 was advanced.
Key Takeaways
Edgewise Therapeutics reported financial results for the first quarter of 2021, highlighting a successful IPO that generated $202.4 million in gross proceeds and the advancement of EDG-5506 in clinical development. The company's cash and marketable securities reached $309.9 million as of March 31, 2021.
Completed a successful $202.4 million Initial Public Offering (IPO).
Cash and marketable securities totaled $309.9 million as of March 31, 2021.
Initiated Phase 1 MAD study of EDG-5506 for Duchenne and Becker muscular dystrophy (DMD and BMD).
Appointed Joanne Donovan, M.D., Ph.D., as Chief Medical Officer (CMO).
Edgewise Therapeutics
Edgewise Therapeutics
Forward Guidance
The company expects to report topline MAD data in healthy volunteers and BMD patient data later in 2021.